Amendment S.3102

Summary

The bill adds new sections to Massachusetts law that obligate the state employee health plan and Medicaid managed‑care plans to pay for biomarker tests when they are supported by FDA approval, CMS coverage determinations, or recognized clinical guidelines. It also sets strict timelines for prior‑authorization responses and provides a clear appeals process. The goal is to ensure timely access to precision‑medicine tests and reduce the need for repeat biopsies.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Topics

Share